Added value of 3D-vision during robotic pancreatoduodenectomy anastomoses in biotissue (LAEBOT 3D2D): a randomized controlled cross-over trial
Year: 2020
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: BACKGROUND: We tested the added value of 3D-vision on procedure time and surgical performance during robotic pancreatoduodenectomy anastomoses in biotissue. Robotic surgery has the advantage of articulating instruments and 3D-vision. Consensus is lacking on the added value of 3D-vision during laparoscopic surgery. Given the improved dexterity with robotic surgery, the added value of 3D-vision may be even less with robotic surgery. METHODS: In this experimental randomized controlled cross-over trial, 20 surgeons and surgical residents from 5 countries performed robotic pancreaticojejunostomy and hepaticojejunostomy anastomoses in a biotissue organ model using the da Vinci® system and were randomized to start with either 3D- or 2D-vision. Primary endpoint was the time required to complete both anastomoses. Secondary endpoint was the objective structured assessment of technical skill (OSATS; range 12-60) rating; scored by two observers blinded to 3D/2D. RESULTS: Robotic 3D-vision reduced the combined operative time from 78.1 to 57.3 min (24.6% reduction, p < 0.001; 20.8 min reduction, 95% confidence intervals 12.8-28.8 min). This reduction was consistent for both anastomoses and between surgeons and residents, p < 0.001. Robotic 3D-vision improved OSATS performance by 6.1 points (20.8% improvement, p = 0.003) compared to 2D (39.4 to 45.1 points, ± 5.5). CONCLUSION: 3D-vision has a considerable added value during robotic pancreatoduodenectomy anastomoses in biotissue in both time reduction and improved surgical performance as compared to 2D-vision.
Source: Surgical Endoscopy
Authors: Maurice J. W. Zwart, Leia R. Jones, Alberto Balduzzi, Kosei Takagi, Aude Vanlander, Peter B. van den Boezem, Freek Daams, Camiel Rosman, Daan J. Lips, Arthur J. Moser, Melissa E. Hogg, Olivier R. C. Busch, Martijn W. J. Stommel, Marc G. Besselink, For the Dutch Pancreatic Cancer Group
Institutions: Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Erasmus MC, Ghent University Hospital, Ghent University, Radboud University Medical Center, Medisch Spectrum Twente, Beth Israel Deaconess Medical Center, Harvard University, Endeavor Health
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,860
Funder: Maag Lever Darm Stichting
OpenAlex ID: W3041937765
